HCW Other Monday, November 16, 2026 +0.30 Positive

HCW Biologics reports Q3 2026 clinical results and business highlights

HCW Biologics reported Phase 1 trial data for HCW9302 in alopecia areata and showcased clinical data for TRBC platform molecules at SITC2026.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed